Results 11 to 20 of about 264,642 (338)
Blood Science, 2023 Programmed death-ligand 1 (PD-L1), expressed on the surface of tumor cells, can bind to programmed cell death-1 (PD-1) on T cells. The interaction of PD-1 and PD-L1 can inhibit T-cell responses by decreasing T-cell activity and accelerating their ...
Yu-Jie Zhou +7 more
doaj +3 more sources
The function and regulation of PD-L1 in immunotherapy [PDF]
ADMET and DMPK, 2017 PD-L1, also known as B7-H1, is a type I transmembrane protein, which is expressed in different kinds of tumor cells. It is correlated with poor clinical outcome of patients with various types of tumors.
Libin Guo, Yao Lin, Hang Fai Kwok
doaj +4 more sources
Journal of Clinical Pathology, 2017 Programmed death ligand 1 (PD-L1) is the principal ligand of programmed death 1 (PD-1), a coinhibitory receptor that can be constitutively expressed or induced in myeloid, lymphoid, normal epithelial cells and in cancer. Under physiological conditions, the PD-1/PD-L1 interaction is essential in the development of immune tolerance preventing excessive ...
Kythreotou A. +4 more
openaire +4 more sources
Frontiers in Oncology, 2022 The two most common antibody targeting principles in oncology are the induction of direct antitumor effects and the release of antitumor T cell immunity by immune checkpoint blockade. These two principles, however, may be overlapping if the targeted checkpoint molecule is not located on the immune cell but on the tumor cell itself. Secondary resistance
Luise Victoria Claaß +7 more
openaire +3 more sources
PD-L1 Expression in Mastocytosis [PDF]
International Journal of Molecular Sciences, 2019 Programmed death 1 (PD-1), when activated by its ligands PD-L1 and PD-L2, suppresses active immune cells in normal immune regulation to limit autoimmunity and, in tumors, as a mechanism of immune evasion. PD-L1 expression has been described as both a prognostic and predictive marker in many solid and hematologic neoplasms, as targeted therapies against
Margaret Williams +4 more
openaire +4 more sources
Comparison of PD-L1 immunohistochemical assays and the significance of PD-L1 expression in thymoma [PDF]
Journal of Thoracic Disease, 2020 Thymoma is a relatively rare malignancy, which is categorized as thymic epithelial tumor but known as the most common pathology that is developed in the anterior mediastinum. Complete resection is recommended for localized tumors and usually favorable prognosis can be obtained.
Shintaro Yokoyama, Hiroaki Miyoshi
openaire +2 more sources
Cancer Medicine, 2020 Background Intravascular large B‐cell lymphoma (IVLBCL) is a rare form of diffuse large B‐cell lymphoma (DLBCL) arising in extranodal sites. PD‐L1 expression of tumor cells has been reported in IVLBCL cells, but its clinicopathological relevance remains ...
Yuka Suzuki +11 more
doaj +1 more source
Small-molecule PD-L1 inhibitor BMS1166 abrogates the function of PD-L1 by blocking its ER export
OncoImmunology, 2020 Therapeutic monoclonal antibodies against the PD-L1/PD-1 (programmed death ligand-1/programmed cell death protein-1) axis have achieved great successes in cancer treatments, but the development of small-molecule immunomodulators of the pathway has lagged
Fang-Fang Chen +3 more
doaj +1 more source
Establishment of Human PD-1/PD-L1 Blockade Assay Based on Surface Plasmon Resonance (SPR) Biosensor
Bio-Protocol, 2023 Blockade of the programmed cell death protein 1 (PD-1)/PD-ligand 1 (PD-L1) axis is a promising strategy for cancer immunotherapy. Although antibody-based PD-1/PD-L1 inhibitors have shown remarkable results in clinical cancer studies, their inherent ...
Tess Puopolo +6 more
doaj +1 more source
PD‐L1 methylation regulates PD‐L1 expression and is associated with melanoma survival [PDF]
Pigment Cell & Melanoma Research, 2018 AbstractThe aim of this study is to determine the significance of programmed death ligand 1 (PD‐L1 or CD274) methylation in relation to PD‐L1 expression and survival in melanoma. Despite the clinical importance of therapies targeting the PD‐1/PD‐L1 immune checkpoint in melanoma, factors regulating PD‐L1 expression, including epigenetic mechanisms, are ...
Goran Micevic +3 more
openaire +3 more sources